Table III.
Clinical outcome and treatment response characteristics of patients (n=132)
| Variable | n (%) |
|---|---|
| Initial treatment (with collaborative care) | |
| Antipsychotic medication | 111 (84.1) |
| Mood stabilizer | 4 (3) |
| Antipsychotic medication+mood stabilizer | 11 (8.3) |
| Antipsychotic medication+anti-depressant medication | 6 (4.4) |
| Treatment revised | 39 (29.5) |
| Antipsychotic medication (first trial) | |
| Tablet risperidone | 78 (59.1) |
| Tablet olanzapine | 38 (28.8) |
| Others | 5 (3.5) |
| Antipsychotic medication prescribed in combination with | |
| Injection fluphenazine | 20 (15.1) |
| Tablet valproate | 17 (12.8) |
| Antipsychotic medication (next trial) | |
| Tablet clozapine | 24 (18.1) |
| Tablet olanzapine | 12 (9.1) |
| Chlorpromazine equivalents (mg), mean±SD35 | 341±163 |
| Clinical outcome (based on clinician experience) | |
| <50 per cent (poor) | 36 (27.3) |
| 50-75 per cent (partial) | 54 (40.9) |
| >75 per cent (good) | 26 (19.7) |
| Adverse side effects | |
| Extrapyramidal symptoms/syndromes | 7 (5.3) |
| Others | 3 (2.3) |
| Referral for intensive psychiatric care at higher centre | 4 (3) |